Show simple item record

Authordc.contributor.authorMauras, Nelly 
Authordc.contributor.authorRoss, Judith L. 
Authordc.contributor.authorGagliardi, Priscila 
Authordc.contributor.authorYu, Y. Miles 
Authordc.contributor.authorHossain, Jobayer 
Authordc.contributor.authorPermuy, Joseph 
Authordc.contributor.authorDamaso, Ligeia 
Authordc.contributor.authorMerinbaum, Debbie 
Authordc.contributor.authorSingh, Ravinder J. 
Authordc.contributor.authorGaete, Ximena 
Authordc.contributor.authorMericq, Verónica 
Admission datedc.date.accessioned2018-03-20T19:35:11Z
Available datedc.date.available2018-03-20T19:35:11Z
Publication datedc.date.issued2016-12
Cita de ítemdc.identifier.citationJ Clin Endocrinol Metab, December 2016, 101(12):4984 – 4993es_ES
Identifierdc.identifier.other10.1210/jc.2016-2891
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/146911
Abstractdc.description.abstractContext: Growth of short children in puberty is limited by the effect of estrogen on epiphyseal fusion. Objectives: To compare: 1) the efficacy and safety of aromatase inhibitors (AIs) vs GH vs AI/GH on increasing adult height potential in pubertal boys with severe idiopathic short stature (ISS); and 2) differences in body composition among groups. Design: Randomized three-arm open-label comparator. Setting: Outpatient clinical research. Patients: Seventy-six pubertal boys [mean (SE) age, 14.1 (0.1) years] with ISS [height SD score (SDS), -2.3 (0.0)]. Intervention: Daily AIs (anastrozole or letrozole), GH, or AI/GH for 24-36 months. Outcomes: Anthropometry, bone ages, dual x-ray absorptiometry, spine x-rays, hormones, safety labs. Results: Height gain [mean (SE)] at 24 months was: AI, +14.0 (0.8) cm; GH, +17.1 (0.9) cm; AI/GH, + 18.9 (0.8) cm(P < .0006, analysis of covariance). Height SDS was: AI, -1.73 (0.12); GH, -1.43 (0.14); AI/GH, -1.25 (0.12) (P < .0012). Those treated through 36 months grew more. Regardless of treatment duration, height SDS at near-final height [n = 71; age, 17.4 (0.2) years; bone age, 15.3 (0.1) years; height achieved, similar to 97.6%] was: AI, -1.4 (0.1); GH, -1.4 (0.2); AI/GH, -1.0 (0.1) (P = .06). Absolute height change was: AI, +18.2 (1.6) cm; GH, +20.6 (1.5) cm; AI/GH, + 22.5 (1.4) cm (P = .01) (expected height gain at -2.0 height SDS, +13.0 cm). AI/GH had higher fat free mass accrual. Measures of bone health, safety labs, and adverse events were similar in all groups. Letrozole caused higher T and lower estradiol than anastrozole. Conclusions: Combination therapy with AI/GH increases height potential in pubertal boys with ISS more thanGHand AI alone treated for 24-36 months with a strong safety profile.es_ES
Patrocinadordc.description.sponsorshipThrasher Research Fund National Institutes of Health from the National Center for Advancing Translational Sciences UL1TR000135es_ES
Lenguagedc.language.isoenes_ES
Publisherdc.publisherEndocrine Soces_ES
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
Sourcedc.sourceJournal of Clinical Endocrinology & Metabolismes_ES
Títulodc.titleRandomized trial of aromatase inhibitors, growth hormone, or combination in pubertal boys with idiopathic, short staturees_ES
Document typedc.typeArtículo de revista
Catalogueruchile.catalogadorpgves_ES
Indexationuchile.indexArtículo de publicación ISIes_ES


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Chile
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile